PMID: 15356414Sep 10, 2004

The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists

Journal of Clinical Psychopharmacology
John W NewcomerAntony D Loebel

Abstract

A nationwide survey in 2003 of 300 randomly selected psychiatrists who routinely treat schizophrenia with atypical antipsychotic therapy was conducted to ascertain practice patterns and attitudes regarding metabolic disturbances during atypical antipsychotic therapy with an emphasis on how these perceptions impact therapeutic decision making. Psychiatrists generally believe that some atypical antipsychotic drugs are associated with metabolic disturbances and that atypical antipsychotics differ in their risk for metabolic disturbances. A majority of respondents (82%) believed that patients with schizophrenia-even those not receiving atypical antipsychotic therapy-are at greater risk for metabolic abnormalities than the general population. A majority of respondents recognized weight gain and diabetes mellitus (59% and 51%, respectively) as potential metabolic complications of atypical antipsychotic therapy, while only some recognized dyslipidemia and certain acute metabolic decompensations like diabetic ketoacidosis (22% and 2%, respectively). Large minorities of respondents (48% and 43%) indicated a willingness to risk weight gain and/or diabetes for the benefits of atypical antipsychotics, possibly because metabolic issues were...Continue Reading

References

Sep 8, 2010·European Archives of Psychiatry and Clinical Neuroscience·Marc De HertJ Peuskens
Jun 7, 2005·Current Psychiatry Reports·Prakash S Masand, Rajnish Mago
Mar 7, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nicholas M WallingfordMichael A Cowley
Nov 11, 2008·Schizophrenia Bulletin·Alexander S YoungKirk McNagny
Oct 15, 2008·Current Opinion in Psychiatry·Jonathan M AmielJohn W Newcomer
Nov 19, 2011·Journal for Healthcare Quality : Official Publication of the National Association for Healthcare Quality·David ScottBrenda Happell
Oct 14, 2010·BMC Psychiatry·Noel CollinsCarol Paton
Jun 1, 2006·Clinical Practice and Epidemiology in Mental Health : CP & EMH·L HanssensJ Peuskens
Oct 5, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Lars Vedel KessingPer Kragh Andersen
Mar 1, 2009·Revista de psiquiatrí́a y salud mental·Marc De HertHans-Jürgen Möller
Mar 19, 2009·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Marc De HertR van Winkel
May 18, 2006·Behavioral Sciences & the Law·Douglas A Smith, Peter F Buckley
Jan 30, 2007·Current Medical Research and Opinion·Terence A Ketter, Dan W Haupt
Jun 25, 2015·Pharmacogenomics·Angela M Devlin, Constadina Panagiotopoulos
Apr 29, 2015·Journal of Child and Adolescent Psychopharmacology·Angie Mae RoddayLaurel K Leslie
Jan 21, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·A VentriglioA Bellomo
Dec 5, 2015·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Jonathan LaugharneMilan Dragovic
May 1, 2008·Journal of the American Psychiatric Nurses Association·Barbara E WolfeAdrian T Smith
Nov 13, 2012·Journal of Attention Disorders·R Christopher SheldrickJohn B Wong
Jul 9, 2008·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Garry WalterJoseph Rey
May 25, 2006·Current Opinion in Psychiatry·A J Mitchell, Darren Malone
Apr 28, 2006·Current Opinion in Psychiatry·Peter F Buckley, Nitin Shendarkar
Jun 3, 2008·Human Psychopharmacology·Hélène VerdouxAudrey Cougnard
Jan 12, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Prakash S Masand
May 28, 2014·Journal of the Chinese Medical Association : JCMA·Hsien-Jane ChiuTsuo-Hung Lan
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Pierre Chue, Raphael Cheung
Aug 2, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Marc De HertA J Mitchell
May 28, 2019·Expert Opinion on Pharmacotherapy·Donatella MarazzitiLiliana Dell'Osso
Apr 28, 2010·Expert Review of Neurotherapeutics·Roger S McIntyre
May 4, 2012·Pharmacoepidemiology and Drug Safety·Stacie B DusetzinaHaiden A Huskamp
Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·Marc De HertJ Peuskens
Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·A HealdChristoph U Correll
Jun 3, 2011·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Marc De HertChristoph U Correll

Citations

Jan 1, 1996·Comprehensive Psychiatry·S MukherjeeP L Scapicchio
Nov 3, 1998·Biological Psychiatry·D A WirshingW C Wirshing
Jun 5, 1999·The American Journal of Cardiology·S M Grundy
Jun 1, 2000·The American Journal of Psychiatry·D C HendersonD C Goff
Mar 10, 2001·The Journal of Clinical Psychiatry·A PredaM B Bowers
Apr 26, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R S McIntyreS H Kennedy
Jun 8, 2001·The Journal of Pediatrics·K A Selva, S M Scott
Sep 20, 2001·The Journal of Clinical Psychiatry·D C HendersonD Hayden
Dec 19, 2001·The American Journal of Medicine·Elizabeth A KollerG Dubitsky
Feb 5, 2002·Expert Opinion on Pharmacotherapy·M M Kato, P J Goodnick
Apr 3, 2002·Archives of General Psychiatry·John W NewcomerGregg Selke
Jul 20, 2002·Pharmacotherapy·Elizabeth A Koller, P Murali Doraiswamy
Nov 5, 2002·Schizophrenia Research·Daniel R WilsonConnie Hammond
Nov 28, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Karin HedenmalmOlav Spigset
Dec 31, 2002·Psychoneuroendocrinology·Henry A Nasrallah
Jun 25, 2003·Pharmacotherapy·Elizabeth A KollerBruce S Schneider
Mar 9, 2004·The Journal of Clinical Psychiatry·American Diabetes AssociationNorth American Association for the Study of Obesity

Related Concepts

Metabolic Process, Cellular
Prescribing Patterns, Physician
Antipsychotic Effect
Thyroid Hormone Metabolism, Abnormal
Atypical Antipsychotic [EPC]
Schizophrenia
Awareness
Dyslipidemias
Antipsychotic Agents
Surfactant Metabolism Dysfunction, Pulmonary,1

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here